Standout Papers
Citation Impact
Citing Papers
Innate and Adaptive Immunity Cooperate Flexibly to Maintain Host-Microbiota Mutualism
2009 StandoutScienceNobel
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases
2007 Standout
Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine.
1988
Gastrointestinal ulcerations induced by anti-inflammatory drugs in rats
1990
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2007
Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors
2001
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
2004 Standout
Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction
2002
Hypersensitivity from Intravenous Iron Products
2014
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
2009 Standout
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 Standout
Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
1995 StandoutNobel
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
2005
The Retrovirus Epidemiology Donor Study (REDS): rationale and methods
1995
Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters
1991
Patient Risk Factors for Adverse Drug Events in Hospitalized Patients
1999
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery
2003
The Idle Intravenous Catheter
1992
Association Between Naproxen Use and Protection Against Acute Myocardial Infarction
2002
Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS)
2013
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
2011
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
1996 Standout
Endometriosis
2009 Standout
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
2000 Standout
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
2005 Standout
The mechanism of action of aspirin
2003 Nobel
Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs
1991
Non‐Steroidal Anti‐Inflammatory Drugs, Cyclooxygenase‐2 and the Bone Healing Process
2007
Epidemiologic Evidence on the Association Between Peptic Ulceration and Antiinflammatory Drug Use
1989
COX-2 Inhibitors and Their Role in Gynecology
2002
COX-2 inhibition and colorectal cancer
2004
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
What a difference a year makes: Reflections on the ACR recommendations for the medical management of osteoarthritis
2001
Effect of Selective Cyclooxygenase 2 Inhibitors and Naproxen on Short-term Risk of Acute Myocardial Infarction in the Elderly
2003
Improving Safety with Information Technology
2003 Standout
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study
2004
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study
2005
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
2005 Standout
Iron Storage Indices: Novel Predictors of Bacteremia in Hemodialysis Patients Initiating Intravenous Iron Therapy
2004
Guideline for Prevention of Intravascular-Device–Related Infections
1996
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
2003
The Risk of Bloodstream Infection in Adults With Different Intravascular Devices: A Systematic Review of 200 Published Prospective Studies
2006
Guideline for Prevention of Intravascular-Device-Related Infections
1996
Platelet Activation and Atherothrombosis
2007 Standout
Using Computerized Data to Identify Adverse Drug Events in Outpatients
2001
Prevention of Peripheral Venous Catheter Complications With an Intravenous Therapy Team
1998
Guidelines for the Prevention of Intravascular Catheter–Related Infections
2002
Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP)
2010
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
2004 Standout
Epidemic carbon monoxide poisoning following a winter storm
1997
Trends in Opioid Analgesic Abuse and Mortality in the United States
2015 Standout
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
1995 Standout
NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection
2001
Cyclooxygenase-2???Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients
2001
Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention
2003
Carbon Monoxide Poisoning
1998 Standout
Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs
1999 Standout
Emerging causes of iron deficiency anemia refractory to oral iron supplementation
2013
Monitoring risk: Post marketing surveillance and signal detection
2009
Therapeutic antibiotic monitoring: Surveillance using a computerized expert system
1990
Emergency health impact of a severe storm
1989
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
1994
Routine care of peripheral intravenous catheters versus clinically indicated replacement: randomised controlled trial
2008
Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk
2004
Design, synthesis, and biological evaluation of linear 1-(4-, 3- or 2-methylsulfonylphenyl)-2-phenylacetylenes: A novel class of cyclooxygenase-2 inhibitors
2005
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Low-Dose Aspirin for the Prevention of Atherothrombosis
2005
Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis
2002
Carbon monoxide poisoning during ice storms: A tale of two cities
1997
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
2001
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
2002
Safety of Peripheral Intravenous Catheters in Children
1999
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
The Risk of Transfusion-Transmitted Viral Infections
1996 Standout
Risk Factors for Infusion-related Phlebitis with Small Peripheral Venous Catheters
1991
Adverse Drug Events in Ambulatory Care
2003 Standout
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 Standout
Guidelines for the Prevention of Intravascular Catheter-related Infections
2011 Standout
Cancer-related inflammation
2008 StandoutNature
An Intervention to Decrease Catheter-Related Bloodstream Infections in the ICU
2006 Standout
A marker for Stevens–Johnson syndrome
2004 StandoutNature
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program
2003
Safety of prolonging peripheral cannula and IV tubing use from 72 hours to 96 hours
1998
Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the United States
1997 Standout
Chlorhexidine–Alcohol versus Povidone–Iodine for Surgical-Site Antisepsis
2010 Standout
Reduction of unnecessary intravenous catheter use. Internal medicine house staff participate in a successful quality improvement project
1994
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
2004
Bias in meta-analysis detected by a simple, graphical test
1997 Standout
Platelet-Active Drugs
2001
Anemia of Chronic Disease
2005 Standout
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
2004
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice
2002
Nimesulide in the Treatment of Patients Intolerant of Aspirin and other NSAIDs
1996
Quantitative tip culture methods and the diagnosis of central venous catheter-related infections
1992
A Computer-Assisted Management Program for Antibiotics and Other Antiinfective Agents
1998 Standout
A Fluorogenic Aryl Fluorosulfate for Intraorganellar Transthyretin Imaging in Living Cells and in Caenorhabditis elegans
2015 StandoutNobel
Erythropoietin, iron, and erythropoiesis
2000
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 Standout
Preventing Complications of Central Venous Catheterization
2003 Standout
Cost-Conscious Prescribing of Nonsteroidal Anti-inflammatory Drugs for Adults With Arthritis
1992
Evaluation of dressing regimens for prevention of infection with peripheral intravenous catheters. Gauze, a transparent polyurethane dressing, and an iodophor-transparent dressing.
1987
The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis
1988 StandoutScience
The Sonogashira Reaction: A Booming Methodology in Synthetic Organic Chemistry
2007 Standout
Current issues in developing a strategy for dealing with the acquired immunodeficiency syndrome.
1986
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
2001 Standout
Culture-Independent Analysis of Indomethacin-Induced Alterations in the Rat Gastrointestinal Microbiota
2006
Microparticulate-Induced Phlebitis
1985
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
2001 StandoutScience
Development of a computerized adverse drug event monitor.
1991
Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients
1990
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction
2005
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
2005 Standout
Adventures in vascular biology: a tale of two mediators
2006
Erythropoietin, iron, and erythropoiesis.
2000
Iron Supplementation in Nephrology and Oncology: What Do We Have in Common?
2011
Iron-Deficiency Anemia
2015 Standout
Erythropoietin, iron, and erythropoiesis
2000
High dose intravenous iron: a note of caution
2002
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
2001 Standout
Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease
2003
Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia
2014
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety
2010
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
2009 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Cutaneous Drug Reactions
2001
Chitosan Chemistry and Pharmaceutical Perspectives
2004 Standout
Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
2004
Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population
2003
The risk of cardiovascular thrombotic events with selective cyclooxygenase‐2 inhibitors
2002
Works of Gerald A. Faich being referenced
Comparative Mortality Associated With Ziprasidone and Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)
2010
Iron Administration and Clinical Outcomes in Hemodialysis Patients
2002
Troglitazone (Rezulin) and hepatic injury
2001
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
2000 Standout
Verapamil use in patients with cardiovascular disease: An overview of randomized trials
1998
Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans
1999
AN EPIDEMIOLOGIC STUDY OF THE RISKS ASSOCIATED WITH PERIPHERAL INTRAVENOUS CATHETERS
1983
Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib**The investigators had full access to the data and complete control over the design, conduct analysis, interpretation, and description of the study. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or in writing the report. The views expressed are those of the investigators alone.
2003
Iincidence and Hospitalkation Patterns of Insulkin-dependent Diabetes Mellitus
1982
National Adverse Drug Reaction Surveillance: 1985
1987
Comparison of thromboembolic events in patients treated with Celecoxib, a Cyclooxygenase-2 specific inhibitor, versus Ibuprofen or Diclofenac
2002
Results of nationwide screening of blood and plasma for antibodies to human T‐cell lymphotrophic III virus, type III
1986
National adverse drug reaction reporting. 1984-1989.
1991
The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)
2008
Adverse-Drug-Reaction Monitoring
1986
Administration of Parenteral Iron and Mortality among Hemodialysis Patients
2004
310 – Comparative mortality associated with ziprasidone vs. olanzapine in real-world use: The ziprasidone observational study of cardiac outcomes (zodiac)
2008
Blizzard morbidity and mortality: Rhode Island, 1978.
1979
National Adverse Drug Reaction Surveillance
1988
Ulcerogenicity of piroxicam: an analysis of spontaneously reported data.
1987